Part D Muddies Script Counts
This article was originally published in RPM Report
Executive Summary
Prescription tracking data from companies like IMS Health have shown a disproportionate increase in volume since the start of the Part D benefit in January, according to an analysis by Prudential Securities analyst Tim Anderson. One reason is in the way the Medicare drug benefit appears to increase the number of new prescriptions for brands.
You may also be interested in...
Tilting the Contracting Scales: Part D Plans Have Advantages Over Manufacturers in 2008
Contracting between pharma companies and Part D plan sponsors that took place last year for 2007 pricing and formulary placement was a relatively straightforward process. This year will be more interesting.
Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly
Pharma companies say Part D is a simple trade: increased volume in exchange for decreased prices. Six months into the program, the deal is working out very well for manufacturers-but don't expect anyone to celebrate just yet.
Big Pharma's Secret Weapon
Pharma companies say Medicare Part D is a simple trade: increased volume in exchange for decreased prices. Six months into the program, the deal is working out very well for manufacturers-but don't expect anyone to celebrate just yet.